BridgeBio Pharma Research and Development Expenses 2018-2026 | BBIO
BridgeBio Pharma annual/quarterly research and development expenses history and growth rate from 2018 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
- BridgeBio Pharma research and development expenses for the quarter ending March 31, 2026 were $0.127B, a 13.65% increase year-over-year.
- BridgeBio Pharma research and development expenses for the twelve months ending March 31, 2026 were $0.467B, a 2.05% decline year-over-year.
- BridgeBio Pharma annual research and development expenses for 2025 were $0.452B, a 10.76% decline from 2024.
- BridgeBio Pharma annual research and development expenses for 2024 were $0.506B, a 11.14% increase from 2023.
- BridgeBio Pharma annual research and development expenses for 2023 were $0.456B, a 14.08% increase from 2022.
|
BridgeBio Pharma Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $452 |
| 2024 | $506 |
| 2023 | $456 |
| 2022 | $399 |
| 2021 | $451 |
| 2020 | $337 |
| 2019 | $210 |
| 2018 | $140 |
| 2017 | $31 |
|
BridgeBio Pharma Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $127 |
| 2025-12-31 | $116 |
| 2025-09-30 | $113 |
| 2025-06-30 | $111 |
| 2025-03-31 | $111 |
| 2024-12-31 | $130 |
| 2024-09-30 | $120 |
| 2024-06-30 | $115 |
| 2024-03-31 | $141 |
| 2023-12-31 | $130 |
| 2023-09-30 | $125 |
| 2023-06-30 | $107 |
| 2023-03-31 | $93 |
| 2022-12-31 | $91 |
| 2022-09-30 | $93 |
| 2022-06-30 | $108 |
| 2022-03-31 | $108 |
| 2021-12-31 | $122 |
| 2021-09-30 | $104 |
| 2021-06-30 | $102 |
| 2021-03-31 | $123 |
| 2020-12-31 | $90 |
| 2020-09-30 | $92 |
| 2020-06-30 | $87 |
| 2020-03-31 | $68 |
| 2019-12-31 | $57 |
| 2019-09-30 | $55 |
| 2019-06-30 | $52 |
| 2019-03-31 | $45 |
| 2018-12-31 | |
| 2018-09-30 | $31 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |